Illumina, Inc. vs Toro Company (The) Common Stock — how do they compare? Illumina, Inc. trades at $272.07 (market cap $40.95B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Illumina, Inc. is far larger — about 4.4× Toro Company (The) Common Stock's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and Toro Company (The) Common Stock for 0 Days on average.
| ILMN | TTC | |
|---|---|---|
Market Cap | $40.95B | $9.27B |
Volume | 1,893,606 | 688,325 |
Sector | Health | Industrials |
52-Week High | $293.69 | $101.76 |
52-Week Low | $93.00 | $67.99 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.31B | $10.17B |
Dividend Yield | — | 1.59% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.
ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →